ORMP: Oramed Pharmaceuticals Inc. Stock

by  •  • Comments Off on ORMP: Oramed Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 87.83
Enterprise Value ($M) 32.49
Book Value ($M) 145.35
Book Value / Share 3.56
Price / Book 0.60
NCAV ($M) 133.29
NCAV / Share 3.26
Price / NCAV 0.66

Profitability (mra)
Return on Invested Capital (ROIC) -0.13
Return on Assets (ROA) -0.09
Return on Equity (ROE) -0.12

Liquidity (mrq)
Quick Ratio 25.19
Current Ratio 25.19

Balance Sheet (mrq) ($M)
Current Assets 143.22
Assets 155.28
Liabilities 9.93
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -12.78
Net Income -19.06
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -8.41
Cash from Investing 105.82
Cash from Financing -52.04

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A BML Investment Partners, L.P. 6.55 29.06
2024-03-22 13D Kidron Nadav 5.70 74.47

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 3,800 33,741 11.26
2025-04-16 688 20,991 3.28
2025-04-15 9,132 29,055 31.43

(click for more detail)

Similar Companies
ONCY – Oncolytics Biotech Inc. ONVO – Organovo Holdings, Inc.
ORGO – Organogenesis Holdings Inc. OTLK – Outlook Therapeutics, Inc.
PALI – Palisade Bio, Inc.


Financial data and stock pages provided by
Fintel.io